| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
REVIEW |
The University of London, School of Pharmacy, Department of Toxicology, 2939 Brunswick Square, London, WC1N 1AX, UK
Correspondence should be addressed to Jane S Fisher; Email: jane.fisher{at}ulsop.ac.uk
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The endocrine system can be regarded as a number of interconnecting and interacting axes. The major regulator of the mature reproductive system is the hypothalamopituitarygonadal (HPG) axis that functions as a classical negative feedback system. This consists of the gonadotrophin-releasing hormone (GnRH) neurons in the hypothalamus (brain) that release GnRH into the portal blood supply. GnRH stimulates the release of gonadotrophins (luteinising hormone (LH) and follicle-stimulating hormone (FSH)) from the gonadotroph cells in the pituitary gland. LH and FSH travel through the systemic circulation and act on the endocrine active cells of gonad (testis or ovary). Within the testis, the Leydig cells secrete testosterone and oestradiol and the Sertoli cells secrete inhibin B. These gonadal signals feedback to the pituitary and hypothalamus to regulate the release of GnRH and the gonadotrophins (IPCS 2002). There is the potential for endocrine disrupting chemicals (EDCs) to act at any level of the HPG axis but there is general support for the view that the development and programming of the axis during fetal life could be the most sensitive window to permanently alter the homeostatic mechanisms of the endocrine system (IPCS 2002).
There is currently no strong data to suggest that environmental EDCs are responsible for the observed degeneration in human male reproductive health, but there are secular trends to suggest that it is declining. There is, however, very good evidence that lifestyle factors (e.g. smoking and/or alcohol consumption) can have an impact on fertility (Sharpe & Franks 2002). Similarly, the notion that all EDCs act by mimicking oestrogen (environmental oestrogens) is too simplistic. The current literature illustrates that EDCs can act as oestrogens, anti-oestrogens, anti-androgens, steroidogenic enzyme inhibitors and can also act via interaction with the thyroid hormones and their receptors, or within the brain and the hypothalamopituitary axis, as well as the immune system (Amaral Mendes 2002). Current thinking suggests that chemicals that interfere with steroid action/production may be of more concern to reproductive health. Two examples of this are the effects of tributyltin (TBT) on marine gastropod populations and the effects of phthalates on laboratory animals. TBT was used in antifouling paints applied to boat hulls. It was subsequently linked to the appearance of imposex (the growth of a penis and vas deferens in the female) in marine snails (Bryan et al. 1986). In female gastropods the growth of the male sex organs can be stimulated by testosterone, and studies have illustrated that TBT increases testosterone levels by inhibiting the enzyme aromatase which converts testosterone to oestradiol (IPCS 2002). Certain phthalate esters (ubiquitously used chemicals in manufacturing) have recently been shown to disrupt male reproductive tract organogenesis when administered to rats during pregnancy. One mechanism by which this occurs is via a large reduction in fetal testosterone synthesis and subsequently androgen levels (Mylchreest et al. 1999, Parks et al. 2000). This reduction in testosterone levels has consequences for the virilization of the male reproductive tract and will be described in more detail later. Although there are cases where single agents have been shown to be the causative chemical (e.g. TBT), it is also important to consider that we are not exposed to single agents in the environment but to a complex mixture of substances. There is currently no real understanding of what the effects of exposure to this mixture are, or whether it poses a real risk to human health. This review will focus on environmental chemicals that have the potential to affect androgen synthesis or action, in particular phthalates, and will make an effort to link the experimental data to issues concerning male reproductive health concerns.
| Problems with male reproductive health |
|---|
|
|
|---|
In general, the reasons for these wide geographical variations in semen quality are not understood, but over time, the data from ongoing prospective studies will provide a resource to establish whether a decreasing trend in sperm counts exists. However, a more relevant question is what is the biological consequence of a reduction in semen quality? A recent study of young Danish men attending medical examinations for compulsory military service between 19961998, found a high proportion to have suboptimal semen quality (Andersen et al. 2000). The mean sperm concentration was 57.4 x 106/ml. However, 48% of men had sperm concentrations below 40 x 106/ml and 25% of men had sperm counts <20 x 106/ml. These cutoffs are relevant as sperm concentrations below 40 x 106/ml have been associated with decreased fecundity and an increased time to pregnancy (Bonde et al. 1998), whereas sperm concentrations below 20 x 106/ml are considered abnormal according to World Health Organization guidelines (World Health Organization 1992). This leaves an as yet unanswered question as to whether the cohort of young men with sub-optimal semen parameters will consequently have decreased fecundity/ fertility.
Testicular cancer
Testicular cancer is often quoted as the commonest cancer of young men. The secular trends across Europe and the United States show that it is increasing in incidence in Caucasian men (Adami et al. 1994, Bergstrom et al. 1996, SEER 2003). There is widespread geographical variation and the incidence of testicular cancer can vary up to 10-fold between countries. In Denmark in 1980, the age standardised incidence rate per 100 000 population was 7.8% whereas in Lithuania it was 0.9%, although in all countries where registry data has been analysed there was an annual increase of 2.33.4% (Adami et al. 1994). The increase in testicular cancer has been linked to a birth cohort effect, suggesting that factors affecting in utero development may be important (Bergstrom et al. 1996). Testicular germ cell cancer arises from cells which have similar characteristics to fetal germ-cells, these pre-malignant cells are termed carcinoma-in situ (CIS) cells (Rajpert-De Meyts et al. 2003). How these cells persist during development and what causes them to proliferate after puberty is not well understood, although it is thought that the factors that promote normal germ cell division may also be important in promoting CIS proliferation. Abnormal intrauterine hormone levels i.e. decreased androgen and/or increased oestrogen levels are believed to be important in the occurrence of testicular cancer (Sharpe & Skakkebaek 1993). Similarly, decreased androgen and/or increased oestrogen levels have also been implicated in the occurrence of cryptorchidism, hypospadias and low sperm counts (Sharpe & Skakkebaek 1993).
Congenital abnormalities (cryptorchidism and hypospadias)
Cryptorchidism and hypospadias are abnormalities normally detected at birth (congenital abnormalities). Cryptorchidism occurs when the testis does not descend into the scrotal sac; this is generally unilateral but can be bilateral. Hypospadias is a developmental abnormality of the penis in which the urethral opening is not located at the tip of the glans penis but can occur anywhere along the shaft. Determining whether there is a real increase in hypospadias and/or cryptorchidism is confounded by changes in diagnostic criteria and recording practices which make the registry data unreliable (Toppari et al. 1996, Paulozzi, 1999, Pierik et al. 2002). Despite this, cryptorchidism is the most common congenital abnormality of the newborn (24% incidence) and trends for hypospadias suggest a progressive increase; based on registry data, hypospadias is the second most common (0.30.7% at birth) congenital malformation (Sharpe 2003). Prospective studies are underway, which employ standardised diagnostic criteria, to collect robust data about the current incidence of cryptorchidism and hypospadias. This will allow the monitoring of future trends and allow international comparisons on the incidences of these disorders. Exposure assessment of adipose tissue (from boys undergoing correction for cryptorchidism) for selected organochlorine compounds has revealed a significant increase in heptachloroepoxide and hexachlorobenzene residues when compared with adipose tissue from children undergoing surgery for other reasons (Hosie et al. 2000). This study focussed on oestrogenic compounds and it would be interesting to know if any differences in chemical residues would be observed if anti-androgenic chemicals were assessed in a similar study.
| Is there a link between these male reproductive health issues? |
|---|
|
|
|---|
|
| The role of androgens in male reproductive tract development |
|---|
|
|
|---|
-reductase. The central role of androgens in driving these developmental processes illustrates why chemicals that can interfere with the synthesis or action of androgens can have deleterious consequences for the developing male genital tract. Administration of the anti-androgen, flutamide (an androgen receptor antagonist), during male reproductive tract development resulted in abnormalities in the formation of the external genitalia - hypospadias and cryptorchidism; internally, agenesis of the epididymis, vas deferens and prostate (Mylchreest et al. 1999). Within the testis, degeneration of the seminiferous epithelium and Leydig cell hyperplasia were common (although this may be a consequence of the cryptorchidism rather than an anti-androgenic effect). The male pups also displayed retained thoracic nipples and a reduced anogenital distance (feminised) which are both indicative of reduced androgen action in fetal life (Mylchreest et al. 1999). In summary, both testosterone- and DHT-mediated male reproductive tract development is impaired by flutamide when administered over the period of reproductive tract differentiation.
| Anti-androgenic compounds in the environment |
|---|
|
|
|---|
The key question remains - are the environmental levels of these compounds sufficient to induce reproductive tract abnormalities in mammals? This is not an easy question to answer. It will involve the study of the effects of multi-component mixtures of compounds to determine the effects on mammalian reproduction. The study of mixture effects in the endocrine disruption field is in its infancy. However, in vitro studies of the effects of xenoestrogen mixtures have been performed using the yeast oestrogen screen (YES) assay, which quantifies oestrogen receptor activation, and in the E-screen assay, which analyses cell proliferation as an endpoint of oestrogen action (Payne et al. 2000, Rajapakse et al. 2002, Silva et al. 2002). These studies have combined compounds such as PCBs (polychlorinated biphenols), genistein, bisphenol A and o,p'-DDT (1,1,1-trichloro o-2,2-bis(p-chlorophenyl)ethane) and using pharmacological prediction models based on the doseresponse curves of the single agents, predicted the effects of the combined mixture. These studies show that the combined effect of mixtures of xenoestrogens is additive and generally follows the concept of concentration addition (Payne et al. 2000, Rajapakse et al. 2002, Silva et al. 2002). In these experiments, 811 xenoestrogens were administered at concentrations below their no observable effect concentration (NOEC), and significant oestrogenic responses were observed. It remains to be seen whether the administration of environmentally relevant concentrations of EDC mixtures will be sufficient to induce reproductive tract effects in vivo. An in vivo study assessing the effects of simultaneously administering vinclozolin and procymidone to rodents has suggested an additive response (Nellemann et al. 2003). However, the mixtures issue is an important consideration in risk assessment strategies, as the data from the in vitro assays illustrate that mixture effects do occur and that studying the action of single compounds is not sufficient to assess risk. Whether in vitro assays are a good model on which to base human risk assessment is a separate issue, but in vivo studies with multicomponent mixtures have to be performed to determine whether the mixtures issue is relevant to human health considerations.
The following sections provide information on a few well-characterised examples of anti-androgenic compounds (vinclozolin, linuron, p,p' DDE and phthalates). These have been selected to show how environmental compounds with the potential to inhibit the action of the androgen receptor or testosterone synthesis can lead to male reproductive tract abnormalities when administered at high doses to rats.
Vinclozolin
Vinclozolin is a dicarboximide fungicide that has two active metabolites, M1 and M2, which have anti-androgenic properties. In vivo and in vitro experiments demonstrate that these compounds act as potent androgen receptor antagonists, and administration to pregnant rats results in abnormalities of androgen-regulated sexual differentiation similar to those induced by flutamide, e.g. reduced anogenital distance, nipple retention, hypospadias, undescended testes and small or absent accessory glands (Gray et al. 2001). Studies have tried to define the sensitive window for exposure to vinclozolin, and have determined that administration to pregnant rats during gestational day (GD) 1419 induced reproductive tract malformations, with treatment over GD1617 causing the most severe malformations (Wolf et al. 2000). This illustrates that the whole period of male reproductive tract differentiation is sensitive to the effects of anti-androgens.
Linuron
Linuron is a urea-based herbicide which acts as a weak androgen receptor antagonist in vitro and in vivo, and disrupts androgen-dependent male reproductive tract development after gestational exposure (Gray et al. 2001). When administered to pregnant rats (GD1418; 100 mg/ kg/day) the male pups displayed a reduced anogenital distance and retention of areolas (Gray et al. 1999). Linuron failed to induce either hypospadias or undescended testes, suggesting that linuron affects testosterone-but not DHT-mediated development, though how this occurs is not known (McIntyre et al. 2002a,b).
p,p'DDE
The persistent pesticide, DDT, is broken down in the environment, and one of its metabolites is p,p'-DDE, which has been shown to act as an androgen receptor antagonist both in vivo and in vitro (Kelce et al. 1995). Studies in which p,p'-DDE was administered to rats during development (GD1418; 100 mg/kg/day) affected androgen-dependent aspects of male development such that it reduced anogenital distance, caused nipple retention and, depending on the rat strain, induced hypospadias (You et al. 1998). Another DDT derivative, methoxychlor and its metabolites, have been shown to interact with both oestrogen receptors and the androgen receptor (AR). The methoxychlor metabolite, 1,1-Trichloro-2,2-bis(4 hydroxyphenyl) ethane, is an oestrogen receptor (ER)-
agonist, an ER-ß antagonist and an AR antagonist (see Gray et al. 2001). This illustrates that chemicals may act by more than one mechanism to induce effects on the exposed population.
These examples serve to illustrate that in rodents the whole period of reproductive tract development is sensitive to the effects of anti-androgens. Even chemicals with the same supposed mechanism of action (i.e. androgen receptor antagonists) can induce different effects after exposure. For example, in utero treatment with linuron has effects on testosterone-mediated development whereas vinclozolin affects both testosterone and DHT target tissues. It is important to remember that many of these chemicals may turn out to be promiscuous in that they will have more than one mechanism of action e.g. HPTE, so care must be taken when labelling chemicals anti-androgens, oestrogens or anti-oestrogens.
Phthalates
For decades there has been concern about the reproductive toxicity of certain phthalate esters. Phthalates are used extensively in manufacturing and cosmetics production. Within rats they are lipophilic but, unlike other compounds such as DDT, they do not bioaccumulate although this may not be the case for all species. The parent phthalate is rapidly metabolised to its monoester (the active metabolite), glucuronidated and excreted. The toxicological literature on phthalates up until 2000 has been thoroughly reviewed by the first expert panel convened by the National Toxicology Programs Centre for the Evaluation of Risks to Human Reproduction (CERHR), and the interested reader is directed to this (Kavlock et al. 2002a,b,c,d ). The analysis of seven urinary phthalate metabolites from a reference population in the USA found the highest metabolites reflected exposure to diethyl phthalate, dibutyl phthalate (DBP) and benzylbutyl phthalate (Blount et al. 2000). These phthalate esters are used extensively in the production of perfume, nail varnish, hairsprays and other personal/cosmetic uses, suggesting that inhalation and dermal exposure may be important routes of exposure. Phthalates are known reproductive and developmental toxicants and the study by Blount et al.(2000) illustrated that women of reproductive age had significantly higher urinary levels of monobutyl phthalate (the metabolite of DBP) than the rest of the reference population (Blount et al. 2000).
Phthalates are a family of compounds and only a few induce male reproductive tract abnormalities. Gray et al.(2000) compared the ability of six phthalate esters (diethylhexyl phthalate, DEHP; benzylbutyl phthalate, BBP; diisononyl phthalate, DINP; dimethyl phthalate, DMP; diethyl phthalate, DEP; dioctyl terephthalate, DOTP; all administered at 750 mg/kg body weight from GD14 to postnatal day (PND) 3) to induce malformations of the reproductive tract (Gray et al. 2000). This study assessed changes in many androgenic endpoints and found that only DEHP, BBP and to a lesser degree DINP induced alterations in all aspects of androgen-regulated male reproductive endpoints (summarised in Table 1
). Although this study did not include DBP there are reports showing that similar effects are produced after in utero exposure to this ester (Mylchreest & Foster 2000, Mylchreest et al. 2002). The period of male reproductive tract development has been demonstrated to be the most sensitive to disruption by phthalates and the types of malformations produced are not dissimilar to those being associated with human TDS. This area of the review will largely focus on the effects of phthalates on testicular development.
|
| Effects of phthalates on testis development |
|---|
|
|
|---|
| Testis development |
|---|
|
|
|---|
|
Indirect evidence for altered Sertoli cell function after in utero phthalate administration during testis development has been obtained. Indeed, all the abnormalities described below might stem from abnormal Sertoli cell function (see Fig. 2
). At GD19 an abnormal interaction between the Sertoli cells and gonocytes has been reported after in utero administration of DBP, which suggested a lack of Sertoli cellgerm cell interaction/adhesion (Fisher et al. 2003). An analogous phenomenon was described during the in vitro co-culture of gonocytes and Sertoli cells. After the administration of DEHP, gonocytes were observed to detach from the Sertoli cells, again suggesting problems with cell adhesion (Li et al. 1998). Data from the postnatal testis illustrate evidence of abnormal Sertoli cell maturation as shown by the lack of expression of the cell cycle marker p27kip in Sertoli cells in dysgenetic areas or Sertoli-cell-only tubules (SCO) (Fisher et al. 2003).
| Leydig cells |
|---|
|
|
|---|
| Testosterone production |
|---|
|
|
|---|
| Peritubular myoid cells/seminiferous cord formation |
|---|
|
|
|---|
| Gonocytes |
|---|
|
|
|---|
| Parallels between human testicular dysgenesis syndrome and rodent in utero exposure to DBP |
|---|
|
|
|---|
| Conclusions |
|---|
|
|
|---|
| Acknowledgements |
|---|
|
|
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
Adami HO, Bergstrom R, Mohner M, Zatonski W, Storm H, Ekbom A, Tretli S, Teppo L, Ziegler H & Rahu M 1994 Testicular cancer in nine northern European countries. International Journal of Cancer 59 3338.[CrossRef][ISI]
Amaral Mendes JJ 2002 The endocrine disrupters: a major medical challenge. Food and Chemical Toxicology 40 781788.[CrossRef][ISI][Medline]
Andersen AG, Jensen TK, Carlsen E, Jorgensen N, Andersson AM, Krarup T, Keiding N & Skakkebaek NE 2000 High frequency of sub-optimal semen quality in an unselected population of young men. Human Reproduction 15 366372.
Bergstrom R, Adami HO, Mohner M, Zatonski W, Storm H, Ekbom A, Tretli S, Teppo L, Akre O & Hakulinen T 1996 Increase in testicular cancer incidence in six European countries: a birth cohort phenomenon. Journal of the National Cancer Institute 88 727733.
Blount BC, Silva MJ, Caudill SP, Needham LL, Pirkle JL, Sampson EJ, Lucier GW, Jackson RJ & Brock JW 2000 Levels of seven urinary phthalate metabolites in a human reference population. Environmental Health Perspectives 108 979982.[CrossRef]
Bonde JP, Ernst E, Jensen TK, Hjollund NH, Kolstad H, Henriksen TB, Scheike T, Giwercman A, Olsen J & Skakkebaek NE 1998 Relation between semen quality and fertility: a population-based study of 430 first-pregnancy planners. Lancet 352 11721177.[CrossRef][ISI][Medline]
Bryan GW, Gibbs PE, Hummerstone LG & Burt GR 1986 The decline of the gastropod Nucella lapillus around south-west England: evidence for the effect of tributyltin from anti-fouling paints. Journal of the Marine Biological Association of the United Kingdom 66 611640.[ISI]
Capel B 2000 The battle of the sexes. Mechanisms of Development 92 89103.[CrossRef][ISI][Medline]
Carlsen E, Giwercman A, Keiding N & Skakkebaek NE 1992 Evidence for decreasing quality of semen during past 50 years. British Medical Journal 305 609613.
Cortes D, Thorup J & Visfeldt J 2003 Multinucleated spermatogonia in cryptorchid boys: a possible association with an increased risk of testicular malignancy later in life? Acta Pathologica Microbiologica et Immunologica Scandinavica 111 2530.
Fisher JS, Macpherson S, Marchetti N & Sharpe RM 2003 Human testicular dysgenesis syndrome: a possible model using in-utero exposure of the rat to dibutyl phthalate. Human Reproduction 18 13831394.
Gray LE Jr, Wolf C, Lambright C, Mann P, Price M, Cooper RL & Ostby J 1999 Administration of potentially antiandrogenic pesticides (procymidone, linuron, iprodione, chlozolinate, p,p'-DDE, and ketoconazole) and toxic substances (dibutyl- and diethylhexyl phthalate, PCB 169, and ethane dimethane sulphonate) during sexual differentiation produces diverse profiles of reproductive malformations in the male rat. Toxicology and Industrial Health 15 94118.
Gray LE Jr, Ostby J, Furr J, Price M, Veeramachaneni DN & Parks L 2000 Perinatal exposure to the phthalates DEHP, BBP, and DINP, but not DEP, DMP, or DOTP, alters sexual differentiation of the male rat. Toxicological Sciences 58 350365.
Gray LE, Ostby J, Furr J, Wolf CJ, Lambright C, Parks L, Veeramachaneni DN, Wilson V, Price M, Hotchkiss A, Orlando E & Guillette L 2001 Effects of environmental antiandrogens on reproductive development in experimental animals. Human Reproduction Update 7 248264.
Hoei-Hansen CE, Holm M, Rajpert-De Meyts E & Skakkebaek NE 2003 Histological evidence of testicular dysgenesis in contralateral biopsies from 218 patients with testicular germ cell cancer. Journal of Pathology 200 370374.
Holm M, Rajpert-De Meyts E, Andersson AM & Skakkebaek NE 2003 Leydig cell micronodules are a common finding in testicular biopsies from men with impaired spermatogenesis and are associated with decreased testosterone/LH ratio. Journal of Patholology 199 378386.
Hosie S, Loff S, Witt K, Niessen K & Waag KL 2000 Is there a correlation between organochlorine compounds and undescended testes? European Journal of Pediatric Surgery 10 304309.[ISI][Medline]
IPCS 2002, Global Assessment of the State-of-the-Science of Endocrine Disruptors. http://ehp.niehs.nih.gov/who/preface.pdf. Eds T Damstra, S Barlow, A Bergman, R Kavlock & G Van Der Kraak.
Irvine DS 1994 Falling sperm quality. British Medical Journal 309 476.
Jorgensen N, Andersen AG, Eustache F, Irvine DS, Suominen J, Petersen JH, Andersen AN, Auger J, Cawood EH, Horte A, Jensen TK, Jouannet P, Keiding N, Vierula M, Toppari J & Skakkebaek NE 2001 Regional differences in semen quality in Europe. Human Reproduction 16 10121019.
Kavlock R, Boekelheide K, Chapin R, Cunningham M, Faustman E, Foster P, Golub M, Henderson R, Hinberg I, Little R, Seed J, Shea K, Tabacova S, Tyl R, Williams P & Zacharewski T 2002a NTP Center for the Evaluation of Risks to Human Reproduction: Phthalates Expert Panel report on the reproductive and developmental toxicity of butyl benzyl phthalate. Reproductive Toxicology 16 453487.[CrossRef][ISI][Medline]
Kavlock R, Boekelheide K, Chapin R, Cunningham M, Faustman E, Foster P, Golub M, Henderson R, Hinberg I, Little R, Seed J, Shea K, Tabacova S, Tyl R, Williams P & Zacharewski T 2002b NTP Center for the Evaluation of Risks to Human Reproduction: Phthalates Expert Panel report on the reproductive and developmental toxicity of di(2-ethylhexyl) phthalate. Reproductive Toxicology 16 529653.[CrossRef][ISI][Medline]
Kavlock R, Boekelheide K, Chapin R, Cunningham M, Faustman E, Foster P, Golub M, Henderson R, Hinberg I, Little R, Seed J, Shea K, Tabacova S, Tyl R, Williams P & Zacharewski T 2002c NTP Center for the Evaluation of Risks to Human Reproduction: Phthalates Expert Panel report on the reproductive and developmental toxicity of diisononyl phthalate. Reproductive Toxicology 16 679708.[CrossRef][ISI][Medline]
Kavlock R, Boekelheide K, Chapin R, Cunningham M, Faustman E, Foster P, Golub M, Henderson R, Hinberg I, Little R, Seed J, Shea K, Tabacova S, Tyl R, Williams P & Zacharewski T 2002d NTP Center for the Evaluation of Risks to Human Reproduction: Phthalates Expert Panel report on the reproductive and developmental toxicity of di-n-butyl phthalate. Reproductive Toxicology 16 489527.[CrossRef][ISI][Medline]
Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA & Wilson EM 1995 Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. Nature 375 581585.[CrossRef][Medline]
Koopman P 2001 Gonad development: signals for sex. Current Biology 11 R481R483.[CrossRef][ISI][Medline]
Koopman P, Munsterberg A, Capel B, Vivian N & Lovell-Badge R 1990 Expression of a candidate sex-determining gene during mouse testis differentiation. Nature 348 450452.[CrossRef][Medline]
Li LH, Jester WF Jr & Orth JM 1998 Effects of relatively low levels of mono-(2-ethylhexyl) phthalate on cocultured Sertoli cells and gonocytes from neonatal rats. Toxicology and Applied Pharmacology 153 258265.[CrossRef][ISI][Medline]
McIntyre BS, Barlow NJ & Foster PM 2002a Male rats exposed to linuron in utero exhibit permanent changes in anogenital distance, nipple retention, and epididymal malformations that result in subsequent testicular atrophy. Toxicological Sciences 65 6270.
McIntyre BS, Barlow NJ, Sar M, Wallace DG & Foster PM 2002b Effects of in utero linuron exposure on rat Wolffian duct development. Reproductive Toxicology 16 131139.[CrossRef][ISI][Medline]
McKinnell C, Atanassova N, Williams K, Fisher JS, Walker M, Turner KJ, Saunders TK & Sharpe RM 2001 Suppression of androgen action and the induction of gross abnormalities of the reproductive tract in male rats treated neonatally with diethylstilbestrol. Journal of Andrology 22 323338.[Abstract]
Mylchreest E & Foster PM 2000 DBP exerts its antiandrogenic activity by indirectly interfering with androgen signaling pathways. Toxicology and Applied Pharmacology 168 174175.[Medline]
Mylchreest E, Cattley RC & Foster PM 1998 Male reproductive tract malformations in rats following gestational and lactational exposure to di(n-butyl) phthalate: an antiandrogenic mechanism? Toxicological Sciences 43 4760.
Mylchreest E, Sar M, Cattley RC & Foster PM 1999 Disruption of androgen-regulated male reproductive development by di(n-butyl) phthalate during late gestation in rats is different from flutamide. Toxi